Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/33848
Type
ArticleCopyright
Restricted access
Embargo date
2022-01-01
Collections
- IOC - Artigos de Periódicos [12747]
Metadata
Show full item record
APRIL PROMOTES B-1 CELL-ASSOCIATED NEOPLASM
Author
Affilliation
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Institut de Génétique Moléculaire de Montpellier. Montpellier CEDEX 5, France.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain.
Universidad Alcalá de Henares.5Unidad Mixta UA/CSIC. Madrid, Spain.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Academical Medical Center. Department of Experimental Immunology. Amsterdam, The Netherlands.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Institut de Génétique Moléculaire de Montpellier. Montpellier CEDEX 5, France.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Institut de Génétique Moléculaire de Montpellier. Montpellier CEDEX 5, France.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain.
Universidad Alcalá de Henares.5Unidad Mixta UA/CSIC. Madrid, Spain.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Academical Medical Center. Department of Experimental Immunology. Amsterdam, The Netherlands.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Institut de Génétique Moléculaire de Montpellier. Montpellier CEDEX 5, France.
Leiden University Medical Center. Department of Clinical Oncology. Leiden, The Netherlands.
Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology. UAM Campus Cantoblanco. Madrid, Spain / Institut de Génétique Moléculaire de Montpellier. Montpellier CEDEX 5, France.
Abstract
A tumor-supporting role for the TNF-like ligand APRIL has been suggested. Here we describe that 9- to 12-month-old APRIL transgenic mice develop lymphoid tumors that originate from expansion of the peritoneal B-1 B cell population. Aging APRIL transgenic mice develop progressive hyperplasia in mesenteric lymph nodes and Peyer’s patches, disorganization of affected lymphoid tissues, mucosal and capsular infiltration, and eventual tumor cell infiltration into nonlymphoid tissues such as kidney and liver. We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
Share